Appraisal of Olezarsen for Treatment of Hypertriglyceridemia
International Journal of Endovascular Treatment and Innovative Techniques · 2024
DOI: 10.61797/ijetit.v5i1.334 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Endovascular Treatment and Innovative Techniques, 2024. Verfasst von Nasser Mikhail. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Olezarsen is antisense antinucleotide under investigation that inhibits synthesis of apolipoprotein C3 (ApoC3) resulting in reduction of plasma triglycerides levels. In a phase 3 clinical trial of patients having familial chylomicronemia syndrome (FCS) with extreme hypertriglyceridemia at baseline (mean plasma triglycerides 2,630 mg/dl), olezarsen 80 mg administered subcutaneously every 4 weeks decreased triglycerides by 43.5 percentage points (95% CI, 69.1 to 17.9; P
Zitieren
APA
Mikhail, N. (2024). Appraisal of Olezarsen for Treatment of Hypertriglyceridemia. International Journal of Endovascular Treatment and Innovative Techniques. https://doi.org/10.61797/ijetit.v5i1.334
Vancouver
Mikhail N. Appraisal of Olezarsen for Treatment of Hypertriglyceridemia. International Journal of Endovascular Treatment and Innovative Techniques. 2024. doi:10.61797/ijetit.v5i1.334
BibTeX
@article{Mikhail2024,
author = {Mikhail, Nasser},
title = {Appraisal of Olezarsen for Treatment of Hypertriglyceridemia},
journal = {International Journal of Endovascular Treatment and Innovative Techniques},
year = {2024},
doi = {10.61797/ijetit.v5i1.334}
}
EUVIMED